Improving Injectable Medicines Prescription in Outpatient Services: A Path Towards Rational Use of Medicines in Iran

Firoozeh Bairami1, Fatemeh Soleymani2,3, Arash Rashidian1,4*

Abstract
Injection is one of the most common medical procedures in the health sector. Annually up to 16 billion injections are prescribed in low- and middle-income countries (LMICs), many of them are not necessary for the patients, increase the healthcare costs and may result in side effects. Currently over 40% of outpatient prescriptions in Iran contain at least one injectable medicine. To address the issue, a working group was established (August 2014 to April 2015) to provide a comprehensive policy brief to be used by national decision-makers. This report is the extract of methods that were followed and the main policy options for improving injectable medicines prescribing in outpatient services. Thirty-three potential policy options were developed focusing on different stakeholders. The panel reached consensus on seven policy options, noting effectiveness, cost, durability, and feasibility of each policy. The recommended policy options are targeted at patients and public (2 policies), insurers (2), physicians (1), pharmacies (1), and the Ministry of Health and Medical Education (MoHME) (1).

Keywords: Injectable Medicines, Outpatient Services, Prescribing, Rational Use of Medicines, Policy Brief

Statement of the Issue and Background
Rational use of medicines is an important component of an effective health system.1 According to the World Health Organization's (WHO's) definition, rational use of medicines means "patients receive medications appropriate to their clinical needs, in doses that meet their own individual requirements, for an adequate period of time, and at the lowest cost to them and their community";2 but when the use of medicines is not compatible to the components of above-mentioned definition, the problem of irrational use of medicine does happen.3 Excessive use of antibiotics, overuse of injections rather than oral formulations, and not taking the full course of medications are among the most common types of inappropriate use of medicines.4 The magnitude of problem in overuse of injections and antibiotics is vast and worldwide and it is much more common in low- and middle-income countries (LMICs).5 Injection is one of the most common medical procedures in the health sector. Annually up to 16 billion injections are prescribed in LMICs. In some setting, over 70% of injections are unnecessary or can be given in other formulations like oral medications.6 Injection is an invasive procedure which can lead to some side effects including bleeding, inflammation, atrophy, nerve injury, and in some cases hypersensitivity reactions such as anaphylactic shock.7 Moreover, high rates of injection can increase the risks of spreading blood borne diseases such as hepatitis B, C, and HIV and incur unnecessary economic burden and costs on users and the health system.8,9,10 Injections should preferably be used in circumstances when safer delivery options (usually oral formulations) of medications are not available or if the patient is not to able to use oral formulations. This issue can be applied more stringently to outpatient settings where by definition patients need less injectable medicines.11

Current Situation
According to the WHO’s estimation the average rate of injections per person per year is about 3.4 in LMICs.12 A review in 1999 by the World Bank noted that 25%-96% of outpatient prescriptions in eight countries contained at least one injection.8 In another review that was conducted in 2000 based on 14 regional division defined by the global burden of disease project of the WHO, in the 10 regions (four predominantly affluent, developed regions excluded) the annual rate of injections per person ranged from 1.7 to 11.3.13 More recent reports from countries confirm the high rate of injections. A study from Bangladesh reported more than 75% of patients received injection.14 This rate for Korea in 2004 was 30.9%.15 India and Cambodia reported 2.9 and 5.9 injections per person per year, respectively.16,17 Studies in Iran reveal that the rate of injections is high. This rate in a study conducted in 2009 was 58%18 and in another study the percentage was reported 41%.19 In 1997 to embed the concept of the rational use of medicines in health system body and to improve the standards of prescription issuance, the National Committee for Rational Use of Drug was established with 44 branches in medical universities across the country. Even though the committee and its subcommittees are working for more than 17 years, yet the rate of injections did not fall within the target range. According to the last report of committee, the rate of injection was estimated at 41%.20 To address the issue, a working group was established to provide a comprehensive policy brief. This report is the extract of methods that were followed and the main policy options for improving injectable medicines prescribing in outpatient services.

Options Extraction
The policy brief reports the processes and results of a policy
development initiative to identify feasible interventions to reduce prescriptions including injectable medicines in outpatient services. The process involved targeted reviews of the literature, key informant consultations, open discussions within the working group, and a consensus development process using nominal group technique.

**Targeted Review of Literature**

We searched the relevant literature to detect current scientific literature referring to the injectable medicines prescribing in outpatient services. The search was performed via online resources using the following research platforms: PubMed, Google Scholar, and Cochrane Library. We also reviewed pharmacology textbooks and WHO guidance\(^{21,22}\) for finding guidelines regarding injectable medicines prescribing in outpatient services.

**Informant Consultations**

In order to consider all factors leading to prescribe/use injectable medicines as much as possible, and also to consider unpublished reports, we interviewed five key informants. Four out of five had key positions in the health system and one had conducted an unpublished study regarding injection prescribing practices in the country.

**Open Discussions Within the Working Group**

To finalize the leading factors and to provide policy options the working group held open discussion sessions with all stakeholders attending the meeting. The participants suggested policy options according to their background.

**Consensus Development**

Accordingly, policy options were provided for each factor.

**Table. Policy Options**

<table>
<thead>
<tr>
<th>Policy Options</th>
<th>Policy Description</th>
<th>Advantages/Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Developing evidence-based clinical guidelines containing recommendations for appropriate prescribing</td>
<td>This policy option targets doctors and is designed in response to a perceived lack of knowledge about effective alternative methods for patient management.</td>
<td>This Policy has a low implementing cost — is expected to have a modest effect for a reasonable period of time. Its feasibility is acceptable.</td>
</tr>
<tr>
<td>2. Enforcing the regulations for dispensing of non-prescription medicines</td>
<td>In response to providing injectable medicines without prescription. It is aimed at pharmacies.</td>
<td>The cost of implementing this policy is low with a good effect in reasonable period of time. However, the feasibility of implementing it is low.</td>
</tr>
<tr>
<td>3. Using mass media to increase public awareness regarding side effects of injection</td>
<td>Public may demand injectable medicines. Using mass media can increase awareness of a large number of people.</td>
<td>We expect a small effect from this policy, effective use of mass media might be costly. The durability and feasibility of implementing is reasonable.</td>
</tr>
<tr>
<td>4. Interventions to change public attitude toward reducing injectable medicines demand</td>
<td>Because of lack of knowledge people think injectable medicines are more effective than other form of medicines. In this regard, increasing knowledge is useful which is possible with changing public attitude.</td>
<td>We can implement this policy easily with a low cost but as the target group is the whole society and the policy is not personalized the effect is low and will decrease during time.</td>
</tr>
<tr>
<td>5. Increasing coordination between the insurer and MoHME monitoring activities</td>
<td>Insurance organizations can play an effective role in managing prescribing injectable medicines and this would be possible with the leverage of monitoring activities.</td>
<td>Even though the cost of implementing this policy is high but the effect is very good and can last for a long time and it can be easily implemented.</td>
</tr>
<tr>
<td>6. Changing the policy of auditing the number of medicinal items in each prescription to the content of prescriptions (Interactions, effectiveness, relevance)</td>
<td>Insurers can check the content of a prescription to watch which form of medicines have been prescribed rather than to check the number of medicinal items (The current policy is to count the number of medicines).</td>
<td>Implementing this policy can be considered as a rational choice because with a reasonable cost we will have a very good effect in a long period of time.</td>
</tr>
<tr>
<td>7. Developing clear guidance for use of injectable medicines in outpatient settings</td>
<td>MoHME as the main policy-maker in the country can control the issue by developing proper guidelines regarding injection.</td>
<td>This policy can be implemented easily by a reasonable cost. However, its effect is low and it can last for a long period of time.</td>
</tr>
</tbody>
</table>

Abbreviation: MoHME, Ministry of Health and Medical Education.
there is a big gap in literature regarding the effectiveness of interventions that can be used to reduce prescriptions containing injectable medicines. We could not find any explicit criteria in pharmacology textbook regarding the standard number of prescribing injections or the condition that we should prescribe injections particularly in outpatient services, although WHO’s handbook for good prescription has recommended that less 10% of outpatient prescriptions should contain injectable medicines. We identified 13 stakeholders (Figure) which seven of them were considered as the main stakeholders and the others as the secondary stakeholders. The interventions were targeted at these stakeholders to guide implementation processes.

The panel reached consensus on seven policy options, noting effectiveness, cost, durability, and feasibility of each policy. To categorize the interventions, we used a previously developed conceptual framework which classifies the interventions to two types including voluntary and non-voluntary (obligatory) interventions. Voluntary interventions include the interventions that target providers’ internal or external motivations. Such categorization helps to define the policies so that both the personal attributes and environmental factors are considered when the interventions are designed and implemented.

We also suggested intervention by targeting stakeholders in this process. The majority of previous studies which have been conducted regarding injections, mainly have considered issues associated to patients such as their beliefs in order to persistency in policy-making and implementation and clear reduction in such inappropriate usage of medicines needs.

Reducing use of injectable medicines in outpatient settings is affected by different factors and stakeholders. Effective reduction in such inappropriate usage of medicines needs persistency in policy-making and implementation and clear

**Conclusion**

Reducing use of injectable medicines in outpatient settings is affected by different factors and stakeholders. Effective reduction in such inappropriate usage of medicines needs persistency in policy-making and implementation and clear
attention in legitimate concerns of the different stakeholders.

Acknowledgments
We would like to thank Dr. Nooshin Mohammad Hosseini, Dr. Bita Mesgarpour, Dr. Forouzan Taheri, Dr. Raziye Keshavarz, Dr. Amir Sarayani, and Dr. Keyvan Tajbaksh for their time and valuable recommendations in this project. We also are grateful to the anonymous reviewers for insightful comments.

Ethical issues
Not applicable.

Competing interests
Authors declare that they have no competing interests.

Authors' contributions
AR and FS designed the study, FB drafted manuscript. AR and FB finalized the draft.

Authors' affiliations
'1Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. '2Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, and Pharmaceutical Economics and Decision-Making Research Center, Tehran University of Medical Sciences, Tehran, Iran. '3National Committee on Rational Medicine Use, Food and Drug Administration, Ministry of Health and Medical Education, Tehran, Iran. '4Department of Global Health and Public Policy, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Additional files
Additional file 1: Contains the Appendix 1.

References